- Home
- NRGV vs NMRA Comparison
NRGV vs NMRA Comparison
Compare NRGV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- NMRA
- Stock Information
- Founded
- NRGV 2017
- NMRA 2019
- Country
- NRGV United States
- NMRA United States
- Employees
- NRGV N/A
- NMRA N/A
- Industry
- NRGV Industrial Machinery/Components
- NMRA
- Sector
- NRGV Miscellaneous
- NMRA
- Exchange
- NRGV Nasdaq
- NMRA Nasdaq
- Market Cap
- NRGV 133.4M
- NMRA 234.5M
- IPO Year
- NRGV N/A
- NMRA 2023
- Fundamental
- Price
- NRGV $1.19
- NMRA $2.14
- Analyst Decision
- NRGV Buy
- NMRA Buy
- Analyst Count
- NRGV 3
- NMRA 8
- Target Price
- NRGV $1.58
- NMRA $7.14
- AVG Volume (30 Days)
- NRGV 1.6M
- NMRA 2.2M
- Earning Date
- NRGV 08-07-2025
- NMRA 08-06-2025
- Dividend Yield
- NRGV N/A
- NMRA N/A
- EPS Growth
- NRGV N/A
- NMRA N/A
- EPS
- NRGV N/A
- NMRA N/A
- Revenue
- NRGV $46,974,000.00
- NMRA N/A
- Revenue This Year
- NRGV $356.46
- NMRA N/A
- Revenue Next Year
- NRGV $34.31
- NMRA N/A
- P/E Ratio
- NRGV N/A
- NMRA N/A
- Revenue Growth
- NRGV N/A
- NMRA N/A
- 52 Week Low
- NRGV $0.60
- NMRA $0.61
- 52 Week High
- NRGV $2.70
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- NRGV 65.05
- NMRA 73.17
- Support Level
- NRGV $0.75
- NMRA $2.09
- Resistance Level
- NRGV $1.64
- NMRA $2.85
- Average True Range (ATR)
- NRGV 0.13
- NMRA 0.31
- MACD
- NRGV 0.05
- NMRA 0.06
- Stochastic Oscillator
- NRGV 49.32
- NMRA 61.35
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.